Showing 2261-2270 of 5644 results for "".
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- AI-based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degenerationhttps://modernod.com/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration/2481490/Researchers supported by the National Eye Institute (NEI) are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within 2 years,
- Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-second-pivotal-phase-3-data-on-nov03-perfluorohexyloctane/2481485/Bausch + Lomb and Novaliq announced that the American Journal of Ophthalmology has
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical